Regeneron Pharmaceuticals, Inc. announced its financial results for the third quarter of 2026, revealing a significant 36% increase in revenues compared to the same period last year. The company reported total revenues of $5.1 billion, driven by strong performances from its flagship products, including Dupixent and EYLEA HD. This impressive growth underscores Regeneron's solid position in the pharmaceutical industry.

On October 30, 2026, Regeneron issued a press release detailing its financial and operating results for the quarter ended September 30, 2026. The filing, which can be accessed under accession number 0000872589-26-000032, highlights the company's ongoing success and strategic initiatives.

Regeneron Pharmaceuticals, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, is a prominent player in the biopharmaceutical sector. The company trades on the Nasdaq under the ticker symbol REGN. It has consistently focused on developing innovative treatments and therapies, positioning itself as a leader in the industry.

The filing indicates that the company's revenues for Q3 2026 reached $5.1 billion, a substantial increase from $3.754 billion in Q3 2025. Notably, Dupixent, a key product for Regeneron, achieved global net sales of $6.5 billion, marking a 35% increase. EYLEA HD also saw a remarkable 62% growth in U.S. net sales, totaling $699 million. Furthermore, Libtayo's global net sales increased by 51% to $550 million.

In addition to strong sales figures, Regeneron reported a GAAP net income of $1.949 billion for the quarter, up from $1.460 billion the previous year, representing a 33% increase. The company also noted that its GAAP earnings per share rose to $18.45, while non-GAAP EPS increased by 70% to $20.07.

Regeneron's growth is further supported by its expanded collaboration with Sanofi, which includes an upfront payment of $1 billion and potential future milestones amounting to $7 billion. This partnership aims to develop next-generation, long-acting immunology antibodies, building on the success of Dupixent.

Looking ahead, Regeneron is optimistic about its pipeline of approximately 50 product candidates. The company anticipates an FDA decision for cemdisiran in generalized myasthenia gravis in the coming month, and its Phase 3 programs in multiple myeloma, lymphoma, anticoagulation, and obesity are progressing well.

Overall, Regeneron's strong Q3 performance reflects its commitment to innovation and growth within the pharmaceutical preparations industry. The filing does not specify what the company plans to do next, but the positive results indicate a promising future.